detinfДЕТСКИЕ ИНФЕКЦИИCHILDREN INFECTIONS2072-81072618-8139Association of Pediatricians and Infection Disease doctors10.22627/2072-8107-2021-20-1-34-38detinf-569Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEW OF THE LITERATUREЗначение интерферонотерапии при COVID-19 у детейThe value of interferon therapy for COVID-19 in childrenhttps://orcid.org/0000-0002-0895-6707МазанковаЛ. Н.MazankovaL. N.

Мазанкова  Людмила Николаевна - д.м.н., профессор, зав. кафедрой детских инфекционных болезней 

 MD, Рrofessor, head of the department of PediatricInfectiousDiseases

mazankova@list.ruhttps://orcid.org/0000-0001-6335-0487ГорбуновС. Г.GorbunovS. G.

Горбунов Сергей Георгиевич - д.м.н., профессор кафедры детских инфекционных болезней

 

MD, Рrofessor of the department of Pediatric Infectious Diseases

gsgsg70@mail.ruhttps://orcid.org/0000-0003-0380-7515СамитоваЭ. Р.SamitovaE. R.

Самитова Эльмира Растямовна - к.м.н., заместитель главного врача по инфекциям  

 PhD, Deputy chief doctor on infections

samitova_rudn@mail.ruФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияRussian Medical Academy of Continuig Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России; ГБУЗ «Детская городская клиническая больница им. З.А. Башляевой» ДЗМРоссияRussian Medical Academy of Continuig Professional Education of the Ministry of Healthcare of the Russian Federation; Children's city clinical hospital of Z.A. Bashlyayeva of the Moscow Department of healthRussian Federation2021090420212013438Copyright © Мазанкова Л.Н., Горбунов С.Г., Самитова Э.Р., 20212021Мазанкова Л.Н., Горбунов С.Г., Самитова Э.Р.Mazankova L.N., Gorbunov S.G., Samitova E.R.This work is licensed under a Creative Commons Attribution 4.0 License.https://detinf.elpub.ru/jour/article/view/569

Представлен обзор литературы о роли интерферонов в иммунопатогенезе COVID-19 и клинической эффективости лекарственных препаратов на основе рекомбинантного интерферона-альфа 2b в лечении детей с новой коронавирусной инфекцией.

Показано ведущее значение интерферонов как факторов первой линии защиты организма от различных вирусов, в том числе и SARS-CoV-2. Многочисленными исследованиями доказывается целесообразность включения препаратов интерферона в схемы терапии COVID-19 у детей как в качестве комбинаций с противовирусными средствами, так и в виде монотерапии.

The article presents a literature review, which provides data on the role of interferons in the immunopathogenesis of COVID-19 and the clinical efficacy of drugs based on recombinant interferon-alpha 2b in the treatment of children with new coronavirus infection. Shown the leading role ofinterferons as factors of the first line of defense against various viruses, including SARS-CoV-2. Numerous studies have proven the feasibility of including interferon preparations in COVID-19 therapyregimens in children, both as combinations with antiviral agents and as monotherapy.

COVID-19SARS-CoV-2интерферон-альфа 2bинтерферонотерапиядетиCOVID-19SARS-CoV-2interferon alpha 2binterferon therapychildrenReferencesPaules C.I., Marston H.D., Fauci A.S. Coronavirus infections—more than just the common cold. JAMA. 2020; 323(8): 707—708. https://doi.org/10.1001/jPaules C.I., Marston H.D., Fauci A.S. Coronavirus infections— more than just the common cold. JAMA. 2020; 323(8): 707—708. https://doi.org/10.1001/jМетодические рекомендации «Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей». МЗ РФ, 24.04.2020.Methodical recommendations "Features of clinical manifestations and treatment of the disease caused by a new coronavirus infection (COVID-19) in children." Ministry of Health of the Russian Federation, 04.24. 2020. (In Russ)]Xiaobing Denga, Xiaoyu Yub, Jianfeng Peic. Regulation of interferon production as a potential strategy for COVID-19 treatment. Сornell Univercity, Submitted on 2 Mar 2020, arXiv: 2003.00751v1 [q-bio.MN] for this versionXiaobing Denga, Xiaoyu Yub, Jianfeng Peic. Regulation of interferon production as a potential strategy for COVID-19 treatment. Сornell Univercity, Submitted on 2 Mar 2020, arXiv: 2003.00751v1 [q-bio.MN] for this versionЛьвов Д.К., Колобухина Л.В., Дерябин П.Г. Коронавирусная инфекция. Тяжелый острый респираторный синдром . Инфекционные болезни: новости, мнения, обучение. 2015; 4:35—42.Lvov D.K., Kolobukhina L.V., Deryabin P.G. Coronavirus infection. Severe acute respiratory syndrome. Infectious Diseases: News, Opinions, Education. 2015; 4:35—42. (In Russ)]Darryl Falzarano, Emmie de Wit, Cynthia Martellaro Inhibition of novel coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 2013; 3:1686.Darryl Falzarano, Emmie de Wit, Cynthia Martellaro Inhibition of novel coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 2013; 3:1686.Vanderheiden А. et al. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. BioRxiv 2020.05.19.105437; DOI: 10.1101/2020.05.19.105437.Vanderheiden А. et al. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. BioRxiv 2020.05.19.105437; DOI: 10.1101/2020.05.19.105437.Lokugamage K.G., Schindewolf C., Menachery V.D. SARS-CoV-2 sensitive to type I interferon pretreatment. BioRxiv. https://doi.org/10.1101/2020.03.07.982264.Lokugamage K.G., Schindewolf C., Menachery V.D. SARS-CoV-2 sensitive to type I interferon pretreatment. BioRxiv. https://doi.org/10.1101/2020.03.07.982264.Абатуров А.Е., Агафонова Е.А., Кривуша Е.Л., Никулина А.А. Патогенез COVID-19. Здоровье ребенка. 2020; 15(2):133— 144.Abaturov A.E., Agafonova E.A., Krivusha E.L., Nikulina A. Pathogenesis of COVID-19. Zdorov’e Rebenka. 2020; 15(2): 133—144. (In Russ) doi: 10.22141/2224-0551.15.1.2020.200598Wong H.H., Fung T.S., Fang S., Huang M., Le M.T., Liu D.X.Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferonregulatory factor 3. Virology.2018;515:165—175. doi:10.1016/j.virol.2017.12.028.Wong H.H., Fung T.S., Fang S., Huang M., Le M.T., Liu D.X.Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferonregulatory factor 3. Virology.2018;515:165—175. doi:10.1016/j.virol.2017.12.028.Kumari G. Lokugamage1, Adam Hage1, Craig Schindewolf1, Ricardo Rajsbaum, Vineet D. Menachery SARS-CoV-2 is sensitive to type I interferon pretreatment. BioRxivpreprint doi: https://doi.org/10.1101/2020.03.07.982264.Kumari G. Lokugamage1, Adam Hage1, Craig Schindewolf1, Ricardo Rajsbaum, Vineet D. Menachery SARS-CoV-2 is sensitive to type I interferon pretreatment. BioRxivpreprint doi: https://doi.org/10.1101/2020.03.07.982264.Erwan Sallarda, François-Xavier Lescureb, , Yazdan Yazdanpanahb, France Mentreb, Nathan Peiffer-Smadjab Type 1 interferons as a potential treatment against COVID-19. Antiviral Research. 2020; 178: 1047913.Erwan Sallarda, François-Xavier Lescureb, , Yazdan Yazdanpanahb, France Mentreb, Nathan Peiffer-Smadjab Type 1 interferons as a potential treatment against COVID-19. Antiviral Research. 2020; 178: 1047913.COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. ABSTRACT, Cytokine and Growth Factor Reviews, Received 11 April 2020. https://doi.org/10.1016/j.cytogfr.2020.05.002.COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. ABSTRACT, Cytokine and Growth Factor Reviews, Received 11 April 2020. https://doi.org/10.1016/j.cytogfr.2020.05.002.Channappanavar R., Fehr A. R. et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. https://www.jci.org/articles/view/126363.Channappanavar R., Fehr A. R. et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. https://www.jci.org/articles/view/126363.Sallarda E., Lescureb F-X., Yazdanpanahb Y.,c, Mentreb F., Nathan Peiffer-Smadjab N.Type 1 interferons as a potential treatment against COVID-19. Antiviral Research. 2020; 178: 104791, Received 26 March 2020; Accepted 3 April 2020.Sallarda E., Lescureb F-X., Yazdanpanahb Y.,c, Mentreb F., Nathan Peiffer-Smadjab N.Type 1 interferons as a potential treatment against COVID-19. Antiviral Research. 2020; 178: 104791, Received 26 March 2020; Accepted 3 April 2020.James M. Sanders, Marguerite L. Monogue, Tomasz Z. Jodlowski, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)A Review. JAMA. 2020; 323(18):1824—1836. doi:10.1001/jama.2020.6019.James M. Sanders, Marguerite L. Monogue, Tomasz Z. Jodlowski, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)A Review. JAMA. 2020; 323(18):1824—1836. doi:10.1001/jama.2020.6019.Cai-Xia Yan , Jia Li, Xin Shen , Li Luo, Yan Li , Ming-Yuan Li Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019. Sichuan Da Xue Xue Bao Yi Xue Ban — 2020, Mar.; 51(2):139—145.DOI: 10.12182/20200360506.Cai-Xia Yan , Jia Li, Xin Shen , Li Luo, Yan Li , Ming-Yuan Li Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019. Sichuan Da Xue Xue Bao Yi Xue Ban — 2020, Mar.; 51(2):139—145.DOI: 10.12182/20200360506.Comparative effectiveness and safety of ribavirin plus interferonalpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia. 2020-03-02, ChiCTR2000029387.Comparative effectiveness and safety of ribavirin plus interferonalpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia. 2020-03-02, ChiCTR2000029387.Chih-Chia Lu , Mei-Yu Chen , Yuh-Lih Chang Potential Therapeutic Agents Against COVID-19: What We Know So Far.J Chin. Med. Assoc. 2020 Apr 1;10.1097, doi: 10.1097/JCMA.0000000000000318. Online ahead of print.Chih-Chia Lu , Mei-Yu Chen , Yuh-Lih Chang Potential Therapeutic Agents Against COVID-19: What We Know So Far.J Chin. Med. Assoc. 2020 Apr 1;10.1097, doi: 10.1097/JCMA.0000000000000318. Online ahead of print.Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 2020; 14:58—60. https://doi.org/10.5582/ddt.2020.01012.Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 2020; 14:58—60. https://doi.org/10.5582/ddt.2020.01012.Yi Xu, Xufang Li, Bing Zhu et al. Characteristics of pediatric SARSCoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine. 2020; 26:502—505.Yi Xu, Xufang Li, Bing Zhu et al. Characteristics of pediatric SARSCoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine. 2020; 26:502—505.Cristina Calvoa, Milagros García López-Hortelanoa, Juan Carlos de Carlos Vicente, Jose Luis Vázquez Martínez, Grupo de trabajo de la Asociación Espanola de Pediatría para el brote de infección por Coronavirus, colaboradores con el Ministerio de Sanidad. Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group. SPANISH ASSOCIATION OF PAEDIATRICS, Anales de Pediatria(English version). 2020; 92(4, April):241.e1-241.e11 https://doi.org/10.1016/j.anpede.2020.02.002.Cristina Calvoa, Milagros García López-Hortelanoa, Juan Carlos de Carlos Vicente, Jose Luis Vázquez Martínez, Grupo de trabajo de la Asociación Espanola de Pediatría para el brote de infección por Coronavirus, colaboradores con el Ministerio de Sanidad. Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group. SPANISH ASSOCIATION OF PAEDIATRICS, Anales de Pediatria(English version). 2020; 92(4, April):241.e1-241.e11 https://doi.org/10.1016/j.anpede.2020.02.002.Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, Raymond Liu et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet,Published:May 08, 2020. https://doi.org/10.1016/S0140-6736(20)31042-4.Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, Raymond Liu et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet,Published:May 08, 2020. https://doi.org/10.1016/S0140-6736(20)31042-4.Sophie Trouillet-Assant, Alexandre Gaymard, Sylvie Pons, JeanChristophe Richard et al. Type I IFN Immunoprofiling in COVID-19 Patients. J. Allergy. Clin. Immunol. 2020, Apr., 29; S0091-6749 (20):30578—9.Sophie Trouillet-Assant, Alexandre Gaymard, Sylvie Pons, JeanChristophe Richard et al. Type I IFN Immunoprofiling in COVID-19 Patients. J. Allergy. Clin. Immunol. 2020, Apr., 29; S0091-6749 (20):30578—9.Lindsey R. Baden, M.D., Eric J. Rubin, M.D., Ph.D. Covid-19 — The Search for Effective Therapy. N. Engl. J. Med., 2020; 382:1851—1852, doi: 10.1056/NEJMe2005477.Lindsey R. Baden, M.D., Eric J. Rubin, M.D., Ph.D. Covid-19 — The Search for Effective Therapy. N. Engl. J. Med., 2020; 382:1851—1852, doi: 10.1056/NEJMe2005477.Qiong Zhou, Virginia Chen, Casey P. Shannon, Xiao-Shan Wei, Xuan Xiang, Xu Wang, Zi-Hao Wang, Scott J. Tebbutt, Tobias R. Kollmann, Eleanor N. Fish Interferon-?2b Treatment for COVID-19. Front. Immunol., 15 May, 2020 https://doi.org/10.3389/fimmu.2020.01061.Qiong Zhou, Virginia Chen, Casey P. Shannon, Xiao-Shan Wei, Xuan Xiang, Xu Wang, Zi-Hao Wang, Scott J. Tebbutt, Tobias R. Kollmann, Eleanor N. Fish Interferon-?2b Treatment for COVID-19. Front. Immunol., 15 May, 2020 https://doi.org/10.3389/fimmu.2020.01061.Дерябин П.Г., Зарубаев В.В. К вопросу о коронавирусной инфекции и перспективах профилактики и лечения препаратами интерферона альфа-2b человеческого рекомбинантного. Инфекционные болезни, 2014; 12(3): 32—34.Deryabin P.G., Zarubaev V.V. On the issue of coronavirus infection and the prospects for prevention and treatment with recombinant human interferon alpha-2b. Infektsionnyye Bolezni=Infectious Diseases, 2014; 12 (3): 32—34. (In Russ)]Кешишян Е.С., Зенина О.М., Кушнарева М.В. Эффективность местной иммунопрофилактики острых респираторных инфекций у детей раннего возраста в общесоматических отделениях. Эффективная фармакотерапия. 2013; 50:50—54.Keshishyan E.S., Zenina O.M., Kushnareva M.V. The effectiveness of local immunoprophylaxis of acute respiratory infections in young children in general somatic departments.Effektivnaya Farmakoterapiya=Effective Pharmacotherapy. 2013; 50: 50-54. (In Russ)Обоснование, опыт лечения и профилактика острых респираторных вирусных инфекций препаратами рекомбинантного ин-терферона: Методические рекомендации. Департамент здравоохранения города Москвы, 2011.Rationale, experience of treatment and prevention of acute respiratory viral infections with recombinant interferon preparations: Methodical recommendations. Moscow City Health Department, 2011. (In Russ)Qiong Zhou1, Virginia Chen2, Casey P. Shannon2, Xiao-Shan Wei1, Xuan Xiang1,Xu Wang1, Zi-Hao Wang1, Scott J. Tebbutt 2,3, Tobias R. Kollmann4 and Eleanor N. Fish Interferon-α2b Treatment for COVID-19. Front. Immunol., 15 May 2020, https://doi.org/10.3389/fimmu.2020.01061.Qiong Zhou1, Virginia Chen2, Casey P. Shannon2, Xiao-Shan Wei1, Xuan Xiang1,Xu Wang1, Zi-Hao Wang1, Scott J. Tebbutt 2,3, Tobias R. Kollmann4 and Eleanor N. Fish Interferon-α2b Treatment for COVID-19. Front. Immunol., 15 May 2020, https://doi.org/10.3389/fimmu.2020.01061.Conor Gruber Impaired Interferon Signature in Severe COVID-19. Nat. Rev. Immunol., 2020, Apr. 30;1, DOI: 10.1038/s41577-020-0335-0.Conor Gruber Impaired Interferon Signature in Severe COVID-19. Nat. Rev. Immunol., 2020, Apr. 30;1, DOI: 10.1038/s41577-020-0335-0.Qiong Zhou, Virginia Chen, Casey P. Shannon, Xiao-Shan Wei, Xuan Xiang,Xu Wang, Zi-Hao Wang, Scott J. Tebbut, Tobias R. Kollmann4 and Eleanor N. Fish Interferon-α2b Treatment for COVID-19. Frontiers in Immunology,May 2020, Volume 11, Article 1061.Qiong Zhou, Virginia Chen, Casey P. Shannon, Xiao-Shan Wei, Xuan Xiang,Xu Wang, Zi-Hao Wang, Scott J. Tebbut, Tobias R. Kollmann4 and Eleanor N. Fish Interferon-α2b Treatment for COVID-19. Frontiers in Immunology,May 2020, Volume 11, Article 1061.

The authors declare that there are no conflicts of interest present.